Egle, A., Steurer, M., Melchardt, T., Weiss, L., Gassner, F. J., Zaborsky, N., . . . Greil, R. (2018). Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): The REVLIRIT CLL-5 AGMT phase I/II study. Ann Hematol.
Citación estilo ChicagoEgle, Alexander, et al. "Fludarabine and Rituximab With Escalating Doses of Lenalidomide Followed By Lenalidomide/rituximab Maintenance in Previously Untreated Chronic Lymphocytic Leukaemia (CLL): The REVLIRIT CLL-5 AGMT Phase I/II Study." Ann Hematol 2018.
Cita MLAEgle, Alexander, et al. "Fludarabine and Rituximab With Escalating Doses of Lenalidomide Followed By Lenalidomide/rituximab Maintenance in Previously Untreated Chronic Lymphocytic Leukaemia (CLL): The REVLIRIT CLL-5 AGMT Phase I/II Study." Ann Hematol 2018.